Dyax Restructures Royalty Loan Agreement, Bringing In $15 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Extension of royalty-sharing with Cowen Healthcare Royalty Partners enables Dyax to fund itself while awaiting FDA’s decision on ecallantide – but at a steep price.